We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

15 hedge funds and large institutions have $5.18M invested in Biotech Acquisition Company Unit in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% less funds holding

Funds holding: 34 → 15 (-19)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

89% less capital invested

Capital invested by funds: $47.6M → $5.18M (-$42.5M)

90% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 21

Holders
15
Holders Change
-19
Holders Change %
-55.88%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
3
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIA
SkyView Investment Advisors
New Jersey
+$32.2K
2
BCM
BCK Capital Management
Connecticut
+$4.21K

Top Sellers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
-$11.5M
2
HIM
HGC Investment Management
Ontario, Canada
-$11.1M
3
MF
Magnetar Financial
Illinois
-$4.45M
4
GCL
Glazer Capital LLC
New York
-$3.11M
5
CCM
Context Capital Management
California
-$1.95M

BIOTU Hedge Fund Activity: Q4 2021 in Review

15 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q4 2021, worth a combined $5.18M — down 89% from $47.6M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of BIOTU and 2 opened new positions — a net loss of 19 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was SkyView Investment Advisors, opening a new position worth an estimated $32.2K. The largest seller was Aristeia Capital, exiting entirely with an estimated $11.5M sold.

  • 15 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q4 2021, down from 34 in Q3 2021.
  • Funds reported $5.18M of Biotech Acquisition Company Unit stock for Q4 2021, down 89% quarter-over-quarter.
  • 2 funds opened new Biotech Acquisition Company Unit positions in Q4 2021 and 21 closed out, a net change of -19 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q4 2021 was SkyView Investment Advisors, an estimated $32.2K added.
  • The largest Biotech Acquisition Company Unit seller in Q4 2021 was Aristeia Capital, an estimated $11.5M sold.

Based on aggregated 13F filings for Q4 2021.